Keytruda and Libtayo are two prominent immunotherapy drugs utilized in the treatment of various cancers. As the field of oncology rapidly evolves, these medications have emerged as significant options for patients battling conditions such as melanoma, lung cancer, and other malignancies. Both drugs are designed to harness the body’s immune system to identify and attack cancer cells, offering a more targeted approach compared to traditional chemotherapy. The mechanisms of action behind Keytruda and Libtayo involve blocking specific proteins that inhibit immune responses, thereby allowing T-cells to recognize and destroy cancerous cells more effectively. The choice between these two therapies can be influenced by various factors, including the specific cancer type,…